Fusion Proteins for Half-Life Extension

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 91-106

  Schmidt, Stefan R ^a  

^a Rentschler Biotechnologie GmbH   (Germany)

Author keywords

Glycosylated peptides; Half life extension; Peptide fusions; Time, toxin, targeting; Triple T paradigm

Indexed keywords

EID: 84886211074     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch6     Document Type: Chapter

References (78)

1. Tryggvason K, Wartiovaara J. (2005) How does the kidney filter plasma? Physiology (Bethesda) 20, 96-101.
2. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. (2010) Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 28(7), 355-362.
3. Beckman RA, Weiner LM, Davis HM. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109(2), 170-179.
4. Sarkar CA, Lowenhaupt K, Horan T, Boone TC, Tidor B, Lauffenburger DA. (2002) Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat. Biotechnol. 20(9), 908-913.
5. Woodnutt G, Violand B, North M. (2008) Advances in protein therapeutics. Curr. Opin. Drug Discov. Deve. 11(6), 754-761.
6. Kontermann RE. (2011) Strategies for extended serum halflife of protein therapeutics. Curr. Opin. Biotechnol. 22(6), 868-876.
7. Peters TJr., (1985) Serum albumin. Adv. Protein Chem. 37, 161-245.
8. Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, et al. (2012) Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat. Commun. 3, 610.
9. Andersen JT, Sandlie I. (2009) The versatile MHC class Irelated FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab. Pharmacokinet. 24(4), 318-332.
10. Wunder A, Stehle G, Sinn H, Schrenk H, Hoffbiederbeck D, Bader F, et al. (1997) Enhanced albumin uptake by rat tumors. Int. J. Oncol. 11(3), 497-507.
11. Cordes AA, Carpenter JF, Randolph TW. (2012) Selective domain stabilization as a strategy to reduce human serum albumin-human granulocyte colony stimulating factor aggregation rate. J. Pharm. Sci. 101(6), 2009-2016.
12. Evans L, Hughes M,Waters J, Cameron J, Dodsworth N, Tooth D, et al. (2010) The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr. Purif. 73(2), 113-124.
13. Zhao HL, Xue C, Wang Y, Li XY, Xiong XH, Yao XQ, et al. (2007) Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation. J. Biotechnol. 131(3), 245-252.
14. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG. (2007) Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25(12), 1411-1419.
15. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, et al. (2005) Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54(1), 251-258.
16. Weimer T,WormsbacherW, Kronthaler U, LangW, Liebing U, Schulte S. (2008) Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb. Haemost. 99(4), 659-667.
17. Schulte S. (2009) Half-life extension through albumin fusion technologies. Thromb. Res. 124(Suppl 2), S6-8.
18. Zhao HL, Xue C, Du JL, Ren M, Xia S, Liu ZM. (2012) Balancing the pharmacokinetics and pharmacodynamics of interferon-a2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy. Mol. Pharm. 9(3), 664-670.
19. Zhan J, Chen Y, Yuan H-Y, Li H, Lu H. (2012) Fusion of HSA influences TNF-a neutralizing activity of shTNFRs. Biotechnol. Lett. 34(3), 417-423.
20. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. (2003) Cytokine traps: multicomponent, high-affinity blockers of cytokine action. Nat. Med. 9(1), 47-52.
21. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184(4), 1968-1976.
22. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, et al. (2010) Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28(2), 157-159.
23. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, et al. (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA 101(26), 9763-9768.
24. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. (2005) Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol Med. 18(3), 294-303.
25. Vallee S, Rakhe S, Reidy T,Walker S, Lu Q, Sakorafas P, et al. (2012) Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway. J. Interferon Cytokine Res. 32(4), 178-184.
26. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20(3), 151-160.
27. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, et al. (2010) SEEDbodies: fusion proteins based on strandexchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23(4), 195-202.
28. Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, et al. (2011) Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono-and bispecific antibodies. Protein Eng. Des. Sel. 24(5), 447-454.
29. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. (2006) An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176(1), 346-356.
30. Correale P, Cusi MG, Tagliaferri P. (2011) Immunomodulatory properties of anticancer monoclonal antibodies: is the "magic bullet" still a reliable paradigm? Immunotherapy 3(1), 1-4.
31. Desjarlais JR, Lazar GA. (2011) Modulation of antibody effector function. Exp. Cell Res. 317(9), 1278-1285.
32. Vaccaro C, Zhou J, Ober RJ,Ward ES. (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23(10), 1283-1288.
33. Fast JL, Cordes AA, Carpenter JF, Randolph TW. (2009) Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. Biochemistry 48(49), 11724-11736.
34. Molineux G, Newland A. (2010) Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br. J. Haematol. 150(1), 9-20.
35. Huang C. (2009) Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol. 20(6), 692-699.
36. Jazayeri JA, Carroll GJ. (2008) Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 22(1), 11-26.
37. Mayle KM, Le AM, Kamei DT. (2012) The intracellular trafficking pathway of transferrin. Biochim. Biophys. Acta 1820(3), 264-281.
38. Chen X, Lee H-F, Zaro JL, Shen W-C. (2011) Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins. MolPharm 8(2), 457-465.
39. Wang Y, Chen Y-S, Zaro JL, Shen W-C. (2011) Receptormediated activation of a proinsulin-transferrin fusion protein in hepatoma cells. J. Control. Release 155(3), 386-392.
40. Kim B-J, Zhou J, Martin B, Carlson OD, Maudsley S, Greig NH, et al. (2010) Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J. Pharmacol. Exp. Ther 334(3), 682-692.
41. Gustavson SM, Chen D, Somayaji V, Hudson K, Baltrukonis DJ, Singh J, et al. (2011) Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 13(11), 1056-1058.
42. Park E, Starzyk RM, McGrath JP, Lee T, George J, Schutz AJ, et al. (1998) Production and characterization of fusion proteins containing transferrin and nerve growth factor. J. Drug Target. 6(1), 53-64.
43. Debinski W. (2002) Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest. 20(5-6), 801-809.
44. Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR. (2008) Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol. Ther. 16(8), 1459-1466.
45. Vanhove B, Laflamme G, Coulon F, Mougin M, Vusio P, Haspot F, et al. (2003) Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 102(2), 564-570.
46. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, et al. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277(38), 35035-35043.
47. Langenheim JF, Chen WY. (2009) Improving the pharmacokinetics/ pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. J. Endocrinol. 203(3), 375-387.
48. Nguyen A, Reyes AE2nd, Zhang M, McDonald P,Wong WLT, Damico LA, et al. (2006) The pharmacokinetics of an albuminbinding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng. Des. Sel. 19(7), 291-297.
49. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, et al. (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 67(1), 254-261.
50. Smith BJ, Popplewell A, Athwal D, Chapman AP, Heywood S, West SM, et al. (2001) Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug. Chem. 12(5), 750-756.
51. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, et al. (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 21(5), 283-288.
52. Walker A, Dunlevy G, Rycroft D, Topley P, Holt LJ, Herbert T, et al. (2010) Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng. Des. Sel. 23(4), 271-278.
53. Nilvebrant J, Alm T, Hober S, Lofblom J. (2011) Engineering bispecificity into a single albumin-binding domain. PLoS ONE 6(10), e25791.
54. Jonsson A, Dogan J, Herne N, Abrahmsen L, Nygren P-A. (2008) Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng. Des. Sel. 21(8), 515-527.
55. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsen L, Ekblad C. (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J. Biol. Chem. 286(7), 5234-5241.
56. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, et al. (2008) Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther. 7(8), 2288-2297.
57. Holliger P, Wing M, Pound JD, Bohlen H, Winter G. (1997) Retargeting serum immunoglobulin with bispecific diabodies. Nat. Biotechnol. 15(7), 632-636.
58. Hutt M, Farber-Schwarz A, Unverdorben F, Richter F, Kontermann RE. (2012) Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J. Biol. Chem. 287(7), 4462-4469.
59. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. (2010) Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. USA 107(52), 22611-22616.
60. Buscaglia CA, Alfonso J, Campetella O, Frasch AC. (1999) Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood. Blood 93 (6), 2025-2032.
61. Alvarez P, Buscaglia CA, Campetella O. (2004) Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences. J. Biol. Chem. 279(5), 3375-3381.
62. Schlapschy M, Theobald I, Mack H, Schottelius M, Wester H-J, Skerra A. (2007) Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng. Des. Sel. 20(6), 273-284.
63. Schellenberger V, Wang C-W, Geething NC, Spink BJ, Campbell A, To W, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol 27(12), 1186-1190.
64. Geething NC, To W, Spink BJ, Scholle MD, Wang C, Yin Y, et al. (2010) Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS ONE 5(4), e10175.
65. Egrie JC, Browne JK. (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br. J. Cancer 84(Suppl. 1), 3-10.
66. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. (1992) Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc. Natl. Acad. Sci. USA 89(10), 4304-4308.
67. Fares F, Guy R, Bar-Ilan A, Felikman Y, Fima E. (2010) Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH. Endocrinology 151(9), 4410-4417.
68. Fares F, Havron A, Fima E. (2011) Designing a long acting erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin b subunit to the N-terminal and C-terminal coding sequence. Int. J. Cell Biol. 2011, 275063.
69. Xu J, Tan L, Goodrum KJ, Kieliszewski MJ. (2007) Highyields and extended serum half-life of human interferon alpha2b expressed in tobacco cells as arabinogalactan-protein fusions. Biotechnol. Bioeng. 97(5), 997-1008.
70. Xu J, Okada S, Tan L, Goodrum KJ, Kopchick JJ, Kieliszewski MJ. (2010) Human growth hormone expressed in tobacco cells as an arabinogalactan-protein fusion glycoprotein has a prolonged serum life. Transgenic Res. 19(5), 849-867.
71. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA. (2006) A thermally responsive biopolymer for intraarticular drug delivery. J. Control. Release 115(2), 175-182.
72. Shamji MF, Betre H, Kraus VB, Chen J, Chilkoti A, Pichika R, et al. (2007) Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum. 56(11), 3650-3661.
73. Bidwell GL3rd, Raucher D. (2010) Cell penetrating elastinlike polypeptides for therapeutic peptide delivery. Adv. Drug Deliv. Rev. 62(15), 1486-1496.
74. Huang Y-S, Wen X-F, Wu Y-L, Wang Y-F, Fan M, Yang Z-Y, et al. (2010) Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer. Eur. J. Pharm. Biopharm. 74(3), 435-441.
75. Wilkinson IR, Ferrandis E, Artymiuk PJ, Teillot M, Soulard C, Touvay C, et al. (2007) A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. Nat. Med. 13(9), 1108-1113.
76. Ferrandis E, Pradhananga SL, Touvay C, Kinoshita C, Wilkinson IR, Stafford K, et al. (2010) Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions. Clin. Sci. 119(11), 483-491.
77. Adams G, Vessillier S, Dreja H, Chernajovsky Y. (2003) Targeting cytokines to inflammation sites. Nat. Biotechnol. 21(11), 1314-1320.
78. Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M, et al. (2012) Molecular engineering of short half-life small peptides (VIP, aMSH and g3MSH) fused to latency-associated peptide results in improved antiinflammatory therapeutics. Ann. Rheum. Dis. 71(1), 143-149.